IPF-ITV-1 / Eco Petroleum Solutions - LARVOL DELTA

Enzolytics, Inc. Engages PCAOB Auditor for December 31, 2020 Year End Audit (Streetinsider.com) - "Enzolytics, Inc....today, announced it has accepted a proposal from a Houston based PCAOB Audit firm to Audit the Company's year-end financial statements, subject to the receipt and acceptance of the engagement letter...In addition, the first tranche of additional funding has been received and with the engagement of the PCAOB auditor, the third tranche from the outside investors along with the first tranche from management should be received this week which will bring the total new funding since September 15, 2020 to $1,300,000.00....One of our top priorities is finalizing the necessary steps for completing the permitting process for our ITV-1 HIV/AIDS therapeutic in Bulgaria."

Commercial • Financing • Human Immunodeficiency Virus • Infectious Disease

Enzolytics, Inc. 2020 Year End Update (Streetinsider.com) - "On December 1, 2020, the combination agreement was completed, and the control block of shares of Enzolytics was transferred in accordance with the terms of the final document...Bids were requested to be provided by mid-January, and the Company anticipates making a decision by the end of January 2021. Our new lab is being opened on the campus of Texas A&M University in the University's Institute for Preclinical Studies. Here we will expand our development capabilities for the production of additional monoclonal antibodies targeting immutable sites on the HIV...Such testing is now scheduled for early 2021 at the University of Strasbourg in Strasbourg, France."

Commercial • Preclinical • Human Immunodeficiency Virus

Enzolytics, Inc. Announces Execution of Binding Letter of Intent for Merger with BioClonetics Immunotherapeutics, Inc. (Streetinsider.com) - "Enzolytics, Inc....today announced the execution of a binding letter of intent (the 'LOI') to merge with BioClonetics Immunotherapeutics, Inc....replacing the earlier non-binding letter signed on September 12, 2020....The Companies plan to conduct binding studies combining the therapeutics produced by both companies to evaluate the beneficial effects and increased binding capability of the BioClonetics Clone 3 antibodies to multiple HIV isolates....Based on the results, the best combination with be tested in primate studies at the California National Primate Research Center University of California, Davis, California."

M&A • Human Immunodeficiency Virus